Sector: MedicalIPXL (OTCBB: IPXL)
Ranking History
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 235 |
Technical : | 230 |
Performance : | 90 |
Overall: | 224 |
Number of Stocks: | 306 |
Scan Date: | 10/20/2009 |
Sector: | Medical |
Funamental : | 237 |
Technical : | 241 |
Performance : | 100 |
Overall: | 237 |
Number of Stocks: | 305 |
Scan Date: | 10/15/2009 |
Sector: | Medical |
Funamental : | 238 |
Technical : | 235 |
Performance : | 99 |
Overall: | 229 |
Number of Stocks: | 305 |
Headlines
- Impax Laboratories Confirms Patent Challenge Relating to TRICOR(R) 48mg and 145mg Tablets
Oct 30, 2009 10:45 AM | ABT, IPXL
- Impax Pharmaceuticals Initiates Second Phase III Trial of IPX066 in Parkinson's Disease
Oct 26, 2009 09:09 AM | IPXL
- Impax Laboratories Settles Pending Litigation for FLOMAX(R)
Oct 07, 2009 07:00 AM | IPXL
- Impax Laboratories Receives Tentative FDA Approval for Generic FLOMAX(R) 0.4mg Capsules
Oct 05, 2009 08:01 AM | IPXL
- Impax Laboratories Commences Shipment of Generic Adderall XR(R) Capsules, 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg
Oct 01, 2009 03:46 PM | IPXL
- BioMed News Bytes: CUR, IPXL, QCOR, VRX
Sep 21, 2009 11:49 AM | GSK, IPXL, VRX
- Impax Laboratories Confirms Patent Challenge Relating to ORACEA(R) Delayed-Release Capsules, 40mg
Sep 21, 2009 07:00 AM | IPXL
- StoredIQ Shares Expertise at IQPC's eDiscovery Pharma, Biotech and Medical Device Conference
Sep 10, 2009 09:01 AM | IPXL
- Impax to Present at the Morgan Stanley Global Healthcare Conference
Sep 08, 2009 08:30 AM | IPXL, MS
- Impax Laboratories to Ring NASDAQ Opening Bell
Aug 24, 2009 06:36 AM | IPXL, NDAQ
- Impax Laboratories Continues Trend of Solid Growth in Revenue, Profit and Earnings for the Third Quarter 2009
Nov 03, 2009 07:52 AM | IPXL
- Impax Laboratories Confirms Patent Challenge Relating to TRICOR® 48mg and 145mg Tablets
Oct 30, 2009 10:52 AM | ABT, IPXL
- Impax Laboratories to Host Third Quarter 2009 Earnings Conference Call and Webcast on November 3
Oct 13, 2009 04:51 PM | IPXL
- Impax Laboratories Settles Pending Litigation for FLOMAX®
Oct 07, 2009 07:54 AM | IPXL
- Impax Laboratories Commences Shipment of Generic Adderall XR® Capsules, 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg
Oct 01, 2009 03:54 PM | IPXL, SHPGY
- Impax Laboratories to Present at the JMP Securities Healthcare Focus Conference
Sep 28, 2009 03:54 PM | IPXL
- Impax Laboratories Confirms Patent Challenge Relating to ORACEA® Delayed-Release Capsules, 40mg
Sep 21, 2009 07:51 AM | IPXL
- Impax to Present at the UBS Global Life Sciences Conference
Sep 16, 2009 03:51 PM | IPXL
- Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinson's Disease
Aug 20, 2009 09:53 AM | IPXL, OMCM
- Impax Laboratories Receives Final FDA Approval for Generic Depakote® Extended-Release 500mg Tablets
Aug 05, 2009 01:53 PM | ABT, IPXL
- Form 4 IMPAX LABORATORIES INC For: May 20 Filed by: OH KIM SUN (10K)
May 22, 2009 01:48 PM
- Form 4 IMPAX LABORATORIES INC For: May 20 Filed by: MARKBREITER MICHAEL (10K)
May 22, 2009 01:44 PM
- Form 4 IMPAX LABORATORIES INC For: May 20 Filed by: BENET LESLIE Z (10K)
May 22, 2009 01:43 PM
- Form 4 FLEMING NIGEL For: May 20 (10K)
May 22, 2009 01:38 PM
- Form 4 TERRERI PETER R For: May 20 (10K)
May 22, 2009 10:26 AM
- Form 4 KOCH ARTHUR A JR For: May 20 (10K)
May 22, 2009 10:26 AM
- Form 4 IMPAX LABORATORIES INC For: May 20 Filed by: NESTOR MICHAEL (10K)
May 22, 2009 10:25 AM
- Form 4 IMPAX LABORATORIES INC For: May 20 Filed by: BURR ROBERT L (10K)
May 22, 2009 10:06 AM
- Form 4 IMPAX LABORATORIES INC For: May 20 Filed by: HSU LARRY (10K)
May 22, 2009 10:04 AM
- Form 4 Mengler Christopher For: May 08 (10K)
May 12, 2009 05:42 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
IPXL
|
Compare to S&P
|
| YTD |
-0.01 %
|
-0.01 %
|
| 4 Weeks |
3.26 %
|
2.16 %
|
| 12 Weeks |
13.56 %
|
10.74 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 0.00 %
|
|
EPS Growth in Last Year: -82.76 %
|
|
Sales Growth in Last Quarter: -0.84 %
|
|
Sales Growth in Last Quarter: -25.75 %
|
|
